NASDAQ: QUREUniqure Nv Stock
$27.57+0.75 (+2.8%)
Updated Jun 12, 2026
QURE Price
$27.57
Fair Value Price
-$8.54
Market Cap
$1.74B
52 Week Low
$8.73
52 Week High
$71.50
P/E
-7.92x
P/B
11.64x
P/S
56.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.09M
Earnings
-$208.87M
Gross Margin
90.6%
Operating Margin
-786.66%
Profit Margin
-1,154.4%
Debt to Equity
4.21
Operating Cash Flow
-$172M
Beta
1.39
Next Earnings
Jul 29, 2026
Ex-Dividend
N/A
Next Dividend
N/A
QURE Overview
uniQure N.V. operates as a specialized gene therapy company, dedicated to pioneering therapeutic solutions for individuals grappling with severe genetic and other debilitating illnesses. The firm's most advanced project, Etranacogene dezaparvovec (designated as AMT-061), is currently progressing through a crucial Phase III pivotal trial, known as HOPE-B, targeting the treatment of hemophilia B. In addition to its flagship program, uniQure is actively developing several other candidates. This includes AMT-130, a gene therapy undergoing Phase I/II clinical assessment for Huntington's disease, and AMT-060, also in Phase I/II clinical trials for hemophilia B. The company's pipeline further extends to AMT-210 for Parkinson's disease, AMT-260 aimed at temporal lobe epilepsy, and AMT-161, which addresses amyotrophic lateral sclerosis. Furthermore, AMT-240 is an early-stage, preclinical product candidate focused on autosomal dominant Alzheimer's disease. Established in 1998, uniQure N.V. maintains its corporate headquarters in Amsterdam, Netherlands.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine QURE's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
QURE
Ranked#120 of 463
Ranked#120 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.56 | A | |
| $53.13 | A | |
| $15.82 | A |
Be the first to know about important QURE news, forecast changes, insider trades & much more!
QURE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how QURE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QURE ($27.57) is overvalued by 422.96% relative to our estimate of its Fair Value price of -$8.54 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
QURE ($27.57) is not significantly undervalued (422.96%) relative to our estimate of its Fair Value price of -$8.54 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
QURE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more QURE due diligence checks available for Premium users.
Valuation
QURE fair value
Fair Value of QURE stock based on Discounted Cash Flow (DCF)
Price
$27.57
Fair Value
-$8.54
Undervalued by
422.96%
QURE ($27.57) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
QURE ($27.57) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
QURE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
QURE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.92x
Industry
16.53x
Market
14.15x
QURE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.64x
Industry
4.85x
QURE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QURE's financial health
Profit margin
Revenue
$3.6M
Net Income
-$53.5M
Profit Margin
-1,502.9%
QURE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
QURE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$778.7M
Liabilities
$629.4M
Debt to equity
4.21
QURE's short-term assets ($615.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QURE's short-term assets ($615.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QURE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
QURE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$38.2M
Investing
$98.6M
Financing
$550.0k
QURE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
QURE vs Biotech Stocks
Uniqure Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.